Product Information
Main Ingredients: Prednisolone
Description: This product is a white or off-white circular, single-faced tablet with a cross score mark.
Pharmacological Actions:
Pharmacodynamics: Adrenocortical hormone drug. Prednisolone has anti-inflammatory, anti-allergic, and immunosuppressive effects. This product can inhibit inflammatory reactions caused by various factors, reduce exudative edema in the early stages of inflammation, thereby alleviating inflammatory symptoms; in the late stages of inflammation, it inhibits collagen and granulation tissue proliferation, preventing adhesions and scar formation. This product exerts anti-allergic and immunosuppressive effects by inhibiting histamine formation and release, preventing or inhibiting cell-mediated immune responses and delayed hypersensitivity reactions, and reducing the expansion of primary immune responses.
Pharmacokinetics: Bioequivalence trials have shown that after a single oral administration of this product and Prednisolone tablets produced by Lloyd Inc. (USA) to Beagle dogs at a dose of 2.5mg per 4.5kg body weight, the two preparations are bioequivalent.
Indications:
Used for the treatment of allergic and inflammatory diseases in dogs. Commonly used for non-specific eczema, summer dermatitis, and burns of the skin; allergic manifestations such as acute urticaria, allergic dermatitis, drug and serum reactions, bronchial asthma, and pollen allergy; eye diseases such as iritis, iridocyclitis, secondary glaucoma, uveitis, and chorioretinitis; ear diseases such as otitis externa; muscle and skeletal diseases such as myositis, rheumatoid arthritis, osteoarthritis, and bursitis; and various chronic or recurrent diseases of unknown etiology such as ulcerative colitis and nephritis.
Dosage and Administration:
Calculated as prednisolone. Oral administration: For dogs, 2.5mg daily per 4.5kg body weight. The total daily dose is divided into 2 equal doses administered at intervals of 6 to 10 hours, for 7 consecutive days. If ineffective, discontinue treatment. The average total daily oral dosage is as follows:
Body Weight (kg) | Dosage (mg) |
2⩽Weight⩽9 | 1.25-5 |
9<Weight⩽18 | 5-10 |
18<Weight⩽36 | 10-20 |
36<Weight⩽73 | 20-40 |
Adverse Reactions:
High doses or long-term use may cause negative nitrogen balance, aggravation of diabetes, petechiae, elevation of serum alkaline phosphatase (SAP) and serum alanine aminotransferase (SALT), weight loss, anorexia, polydipsia and polyuria, vomiting, diarrhea, and Cushing's syndrome.
Precautions:
Do not use in dogs with viral and fungal infections.
Do not use in dogs with peptic ulcers, corneal ulcers, and Cushing's syndrome.
Do not use in pregnant dogs.
Use with caution and control in dogs with diabetes, osteoporosis, thrombophlebitis, hypertension, congestive heart failure, renal insufficiency, and active pulmonary tuberculosis.
When dogs have acute bacterial infections, it should be used in combination with antibacterial drugs.
Since this product inhibits inflammatory responses such as leukocyte infiltration and phagocytosis, prednisolone may mask infection symptoms and aggravate the progression of infection. Therefore, dogs receiving prednisolone treatment should be monitored for concurrent infections. If an infection occurs, appropriate antibacterial measures or discontinuation of the drug must be implemented.
This product should not be used in excess of the recommended dosage, and dogs receiving treatment should be closely monitored.
Withdrawal Period: Not applicable.
Specification: 5mg
Storage: Store in a dark, sealed container.
Validity Period: 24 months